These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 5662373)

  • 41. [Beta blocking agents].
    Lund-Larsen PG
    Tidsskr Nor Laegeforen; 1968 Apr; 88(7):626-30. PubMed ID: 5674185
    [No Abstract]   [Full Text] [Related]  

  • 42. [Therapy of neurocirculatory asthenia using beta-receptor blocking agents].
    Schweitzer P; Klvánová H; Blasková B; Turcsányi L
    Cas Lek Cesk; 1968 Feb; 107(8):242-3. PubMed ID: 5664794
    [No Abstract]   [Full Text] [Related]  

  • 43. [Beta-blocking drugs in coronary insufficiency. Clinical experiences with iproveratril].
    Guadagno L; Giannelli G; Ghiara F; Guadagno P; Zucchelli GP
    Minerva Med; 1967 Sep; 58(77):3288-94. PubMed ID: 6054782
    [No Abstract]   [Full Text] [Related]  

  • 44. Interfaces of psychopharmacology and cardiology--Part two.
    Risch SC; Groom GP; Janowsky DS
    J Clin Psychiatry; 1981 Feb; 42(2):47-59. PubMed ID: 6109718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effects of some adrenergic blocking agents on cardiovascular system].
    Oka K
    Kumamoto Igakkai Zasshi; 1966 Oct; 40(10):1095-103. PubMed ID: 6013682
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical observations on the use of beta-blocking agents in sinusal tachycardia].
    Ravera M
    Minerva Cardioangiol; 1968 Oct; 16(10):1000-3. PubMed ID: 5727885
    [No Abstract]   [Full Text] [Related]  

  • 47. New blocking agents.
    BROWN CH
    Am J Nurs; 1957 Jul; 57(7):877-9. PubMed ID: 13435267
    [No Abstract]   [Full Text] [Related]  

  • 48. Contribution to the clinical evaluation of beta-adrenergic blocking drugs: 1-p-nitrophenyl-2-isopropylaminoethanol (INPEA) as an antagonist of catecholamines in normal persons and in coronary disease patients.
    Piva M; Ongari R
    Arzneimittelforschung; 1968 Feb; 18(2):179-88. PubMed ID: 5695376
    [No Abstract]   [Full Text] [Related]  

  • 49. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The road ahead with beta-blockers: expanding treatment options in cardiovascular disease.
    Hollenberg NK
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):163S-164S. PubMed ID: 16373193
    [No Abstract]   [Full Text] [Related]  

  • 51. [Drugs used in cardiovascular diseases and cytokines].
    Andrzejczak D; Górska D
    Wiad Lek; 2006; 59(3-4):232-7. PubMed ID: 16813270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacologic prevention of cardiovascular diseases--2005].
    Kancz S
    Orv Hetil; 2005 May; 146(20 Suppl 2):1122-31. PubMed ID: 15945241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent advances in cardiovascular pharmacology.
    Frishman WH
    Heart Dis; 1999; 1(2):68-90. PubMed ID: 11720608
    [No Abstract]   [Full Text] [Related]  

  • 54. [Comparative studies on beta-receptor-blocking agents].
    Bender F; Schmidt E; Sieger W
    Verh Dtsch Ges Inn Med; 1968; 74():569-70. PubMed ID: 5714383
    [No Abstract]   [Full Text] [Related]  

  • 55. [Effects of beta-blocking agents on the vasomotor syndrome of the climacteric].
    Gatto A
    Arch Ostet Ginecol; 1968 Apr; 73(2):238-43. PubMed ID: 5706085
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.
    Fletcher GF; Bufalino V; Costa F; Goldstein LB; Jones D; Smaha L; Smith SC; Stone N
    Am J Cardiol; 2007 Mar; 99(6C):1E-35E. PubMed ID: 17378996
    [No Abstract]   [Full Text] [Related]  

  • 57. Take it to heart: talking drugs, supplements, and cardiovascular health with Bob Lefkowitz. Interview by Randy A. Hall.
    Lefkowitz B
    Mol Interv; 2009 Oct; 9(5):220-5. PubMed ID: 19828828
    [No Abstract]   [Full Text] [Related]  

  • 58. Adrenergic receptors: new concepts and implications for cardiovascular therapeutics.
    Colucci WS; Braunwald E
    Cardiovasc Clin; 1984; 14(3):39-59. PubMed ID: 6144390
    [No Abstract]   [Full Text] [Related]  

  • 59. Cerebral hemodynamics during controlled hypotension induced by the continuous infusion of ganglionic blocking agents (hexamethonium, pendiomide and arfonad).
    MOYER JH; MORRIS G
    J Clin Invest; 1954 Aug; 33(8):1081-8. PubMed ID: 13183992
    [No Abstract]   [Full Text] [Related]  

  • 60. Ganglion-blocking agents, hydrazinophthalazines and active principles of Rauwolfia serpentina in the treatment of arterial hypertension.
    RAYNAUD R; D'ESHOUGUES JR
    Alger Medicale; 1955 Jan; 59(1):49-54. PubMed ID: 14361302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.